3 active not recruiting, 1 completed, 1 recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Recurrent Gliosarcoma: new trials by email Literature Review of Recurrent Gliosarcoma trials Research Report on Recurrent Gliosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Atezolizumab, Cabozantinib - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2022-09-23 | 2026-08-25 |
| Pembrolizumab in Treating Patients With Recurrent Glioblastoma Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2015-04-28 | 2026-09-03 |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme temozolomide and bevacizumab - Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma | Phase 2 | Completed | Center for Neurosciences, Tucson | 30 | 2009-04-01 | 2017-03-30 |
Glioblastoma (5) · Gliosarcoma (5) · Astrocytoma (1) · Brain Neoplasms (1) · Glioma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Astrocytoma (4) · Glioma (4) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
pembrolizumab (3) · Specimen Handling (2) · Bevacizumab (1) · Biopsy (1) · Magnetic Resonance Spectroscopy (1) · Surgical Procedures, Operative (1) · Temozolomide (1) · atezolizumab (1) · cabozantinib (1) · efineptakin alfa (1) · gosha-jinki-gan (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Center for Neurosciences, Tucson (1)
United States (5)
Jian L Campian, MD, PhD (1) · Jian L. Campian, MD, PhD (1) · Michael A. Badurddoja, MD (1) · Shiao-Pei S Weathers (1) · Vinay Puduvalli, MD (1)
R01CA288862 (1)